Objective To evaluate the therapeutic effect and safety of inhaling magnesium sulfate on infants with acute bronc-hiolitis. Methods Ninty infants with bronchiolitis were divided into 3 groups randomly and received either magnesium sulfate infusion inhalation or intravenous injection or normal saline inhalation respectively. The change of parameters of each group were observed and compared. Results Magnesium sulfate inhalation group and intravenous injection group were superior to control group in terms of the improvement of blood gas, clinical scores, continuous time of symptoms,signs, hospital days and clinical total efficiency(P

OBJECTIVE To probe into the new method to improve medical environment,and reduce hospital infection causing by the environmental factors.METHODS Using the nanometer photocatalysis technology clinically,to analyze the bacteriostatic effect of medical environment.RESULTS After use of the nanometer photocatalysis spraying material the surface sterilization effect was obvious on the three kinds of environmental objects.The withering away rate of bacterium on the object with total surface was 23.75-38.30%;the vertical surface bacterium withers away rate was 48.77-87.97%,the horizontal surface bacterium withers away rate was 12.50-77.20%,the air bacterium withering away rate was 1.52-60.00%.CONCLUSIONS The nanometer photocatalysis technology to sterilize and purify the medical environment has very good perspectives.

OBJECTIVEFor clarifying the situation of the natural infection of rodents having hemorrhagic fever with renal syndrome (HFRS) virus and to type Hantavirus (HV) using molecular technique in Shenzhen city in 2005, and offering guidance for prevention and control of HFRS.

METHODSData on the host animals was collected from the city of Shenzhen. ELISA and indirect immunofluorscent antibody(IFA) test were applied to the specific antibodies against HV in the sera of captured rats. Direct immunofluorscece assay was adopted to determine HFRS antigens and the lung tissues of the HV infected rats were inoculated into Meriones unguiculata to isolate HV. The whole viral RNA was extracted from the lung tissues of the HV infected rats and amplified the partial M fragments with RT-nested-PCR, using the HV genotype specific primers. The amplified genes were then sequenced, and subjected to genotyping and homology analysis.

RESULTS472 rodents were captured from Shenzhen in 2005. Surveillance on rats demonstrated 9.96% rats carrying HV (with a density of 8.25%) and the main host was Rattus norvegicus. In the blood samples of rats, anti-HV IgG antibodies were detectable in 56 cases by IFA, and proved to be positive in 76 cases by ELISA. We successfully isolated a HV strain designated as SZ2083 from Rattus norvegicus for the first time in Shenzhen and was identified to SEO type by RT-nested-PCR. Compared with the coding region of the M gene of HV L99 virus strain, the homologies of nucleotide among them were 97%, but the homology was 76% of the SZ2083 with HTN 76-118 virus strain.

CONCLUSIONResults showed the existence of natural epidemic areas of HFRS in Shenzhen city. Based on the results of sequencing, it is possible that the Seoul strain of HV might be the predominant serotype of virus harbored.

Animals ; China ; epidemiology ; Cities ; Data Collection ; Enzyme-Linked Immunosorbent Assay ; Fluorescent Antibody Technique, Indirect ; Genotype ; Hantavirus ; classification ; genetics ; isolation & purification ; Hantavirus Infections ; epidemiology ; veterinary ; Rats ; virology ; Rodentia ; virology

OBJECTIVETo study the changes of expression of Survivin mRNA, BCRP mRNA and HER-2 mRNA in breast cancer after TE regimen neoadjuvant chemotherapy, and to find biological markers to predict the efficiency of TE regimen neoadjuvant chemotherapy.

METHODSThe gene expressions were detected by RT-PCR from 56 breast cancer patients before and after TE regimen neoadjuvant chemotherapy (docetaxel and epirubicin). The relationships between these gene expressions and chemotherapy responses were analyzed.

RESULTSThe overall response rate to neoadjuvant chemotherapy was 71.4%, including 8.9% (5/56) with complete response and 62.5% (35/56) with partial response. Pathological complete response was found in 4 cases (7.1%). Stable disease and progression of disease were 23.2% (13/56) and 5.4% (3/56), respectively. The expression of Survivin mRNA after neoadjuvant chemotherapy was 35.7% (20/56), significantly lower than 60.7% (34/56) before neoadjuvant chemotherapy (P = 0.008). The expression of BCRP mRNA after neoadjuvant chemotherapy was 19.6%, significantly lower than 37.5% before neoadjuvant chemotherapy (P = 0.036). The positive rate of HER-2 mRNA expression was 41.1% before the chemotherapy, and reduced to 21.4% after the chemotherapy (P = 0.025). The effective rates of the single positive expression of Survivin mRNA or BCRP mRNA were both lower than that of negative expression (P < 0.05). The level of HER-2 mRNA expression alone was not significantly associated with the effective rate of chemotherapy (P = 0.144). When the expression of all Survivin mRNA, BCRP mRNA and HER-2 mRNA were negative, the effective rate of neoadjuvant chemotherapy was higher than that in patients with positive expression (P = 0.003). The level of Survivin mRNA expression was not significantly associated with BCRP mRNA and HER-2 mRNA (P > 0.05).

CONCLUSIONThe expression of Survivin in combination with BCRP and HER-2 is associated with clinical response to TE neoadjuvant chemotherapy in breast cancer, and can be used as predictive biomarkers for chemosensitivity of TE regimen neoadjuvant chemotherapy for breast cancer.

ATP Binding Cassette Transporter, Sub-Family G, Member 2 ; ATP-Binding Cassette Transporters ; genetics ; metabolism ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Breast Neoplasms ; drug therapy ; metabolism ; surgery ; Carcinoma, Ductal, Breast ; drug therapy ; metabolism ; surgery ; Carcinoma, Lobular ; drug therapy ; metabolism ; surgery ; Disease Progression ; Epirubicin ; administration & dosage ; Female ; Humans ; Inhibitor of Apoptosis Proteins ; genetics ; metabolism ; Mastectomy, Radical ; methods ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Proteins ; genetics ; metabolism ; RNA, Messenger ; metabolism ; Receptor, ErbB-2 ; genetics ; metabolism ; Remission Induction ; Taxoids ; administration & dosage